GANX Stock Summary and Trading Ideas (Gain Therapeutics | NASDAQ:GANX)

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Gain Therapeutics trades on the NASDAQ stock market under the symbol GANX.

As of March 27, 2026, GANX stock price declined to $1.83 with 871,075 million shares trading.

GANX has a beta of 1.52, meaning it tends to be more sensitive to market movements. GANX has a correlation of 0.06 to the broad based SPY ETF.

GANX has a market cap of $70.39 million. This is considered a Micro Cap stock.

In the last 3 years, GANX traded as high as $6.19 and as low as $.89.

The top ETF exchange traded funds that GANX belongs to (by Net Assets): VXF, IWC, IBRN.

GANX has underperformed the market in the last year with a price return of -12.4% while the SPY ETF gained +12.8%. GANX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -41.9% and -33.5%, respectively, while the SPY returned -7.9% and -4.5%, respectively.

GANX support price is $1.76 and resistance is $2.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GANX shares will trade within this expected range on the day.